Corcept Therapeutics Newswire (Page 3)

Corcept Therapeutics Newswire (Page 3)

Comprehensive Real-Time News Feed for Corcept Therapeutics. (Page 3)

Results 41 - 60 of 194 in Corcept Therapeutics

  1. Corcept Therapeutics Incorporated (CORT) Rating Reiterated by FBR & Co.Read the original story w/Photo

    Jun 23, 2016 | AmericanBankingNews.com

    ... investors recently bought and sold shares of CORT. LPL Financial LLC boosted its position in Corcept Therapeutics by 262.1% in the first quarter. LPL Financial LLC now owns 105,000 shares of the company's stock valued at $516,000 after buying an ...

    Comment?

  2. Corcept Therapeutics' (CORT) "Outperform" Rating Reiterated at FBR & Co.Read the original story w/Photo

    Jun 23, 2016 | AmericanBankingNews.com

    ... have recently bought and sold shares of the company. BlackRock Group LTD increased its position in Corcept Therapeutics by 60.8% in the first quarter. BlackRock Group LTD now owns 21,848 shares of the company's stock valued at $103,000 after buying ...

    Comment?

  3. Analysts Anticipate Corcept Therapeutics Incorporated (NASDAQ:CORT)...Read the original story w/Photo

    Jun 20, 2016 | AmericanBankingNews.com

    Shares of Corcept Therapeutics Incorporated have been assigned a consensus broker rating score of 1.75 from the four brokers that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a sell recommendation and three have assigned a strong buy recommendation to the company.

    Comment?

  4. Corcept Therapeutics' (CORT) "Buy" Rating Reaffirmed at FBR & Co.Read the original story w/Photo

    Jun 18, 2016 | AmericanBankingNews.com

    ... investors recently bought and sold shares of the company. D. E. Shaw & Co. Inc. boosted its position in Corcept Therapeutics by 176.3% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 240,709 shares of the company's stock valued at $1,199,000 ...

    Comment?

  5. Corcept Therapeutics Inc. Provides Update Of Progress In Cortisol Modulation Oncology ProgramRead the original story

    Jun 5, 2016 | BioSpace

    The University of Chicago to conduct a Phase 2 trial, supported by Celgene Corporation and Corcept Therapeutics, of mifepristone plus Abraxane to treat patients with TNBC Corcept Therapeutics Incorporated , a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, psychiatric and oncologic disorders by modulating the effects of the stress hormone cortisol, released preliminary efficacy data from its Phase 1/2 trial of mifepristone to treat patients with metastatic . The company also provided an update of developments in other clinical trials of cortisol modulators, including mifepristone, to treat a variety of solid-tumor cancers.

    Comment?

  6. Corcept Therapeutics' (CORT) "Buy" Rating Reiterated at FBR & Co.Read the original story w/Photo

    Jun 5, 2016 | AmericanBankingNews.com

    ... SEC, which is accessible through this hyperlink . Separately, Zacks Investment Research cut shares of Corcept Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, March 30th. This article was first published by ...

    Comment?

  7. FBR & Co. Reiterates Buy Rating for Corcept Therapeutics IncorporatedRead the original story w/Photo

    Jun 4, 2016 | AmericanBankingNews.com

    Corcept Therapeutics traded down 6.88% during mid-day trading on Wednesday, reaching $5.82. The company's stock had a trading volume of 819,585 shares.

    Comment?

  8. New market study, 'Fallopian Tube Cancer - Pipeline Review, H1 2016', has been publishedRead the original story w/Photo

    Jun 3, 2016 | PR-inside.com

    ... Inc., Celldex Therapeutics, Inc., Celsion Corporation, Cerulean Pharma, Inc., Clovis Oncology, Inc., Corcept Therapeutics Incorporated, Critical Outcome Technologies Inc., CTI BioPharma Corp., Dr. Reddy's Laboratories Limited, EirGenix Inc., Eli ...

    Comment?

  9. Corcept Therapeutics Provides Update of Progress in Cortisol Modulation Oncology ProgramRead the original story w/Photo

    Jun 2, 2016 | Freshnews

    The University of Chicago to conduct a Phase 2 trial, supported by Celgene Corporation and Corcept Therapeutics, of mifepristone plus Abraxane to treat patients with TNBC Corcept Therapeutics Incorporated , a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, psychiatric and oncologic disorders by modulating the effects of the stress hormone cortisol, released preliminary efficacy data from its Phase 1/2 trial of mifepristone to treat patients with metastatic . The company also provided an update of developments in other clinical trials of cortisol modulators, including mifepristone, to treat a variety of solid-tumor cancers.

    Comment?

  10. SADIF Analytics releases new summary due diligence report for BioTime, Inc.Read the original story w/Photo

    Jun 2, 2016 | PR-inside.com

    ... .] Ilhavo, Portugal - SADIF Investment Analytics, announces a new summary due diligence report covering Corcept Therapeutics Incorporated [..]

    Comment?

  11. SADIF Analytics releases new summary due diligence report for Lions...Read the original story w/Photo

    Jun 2, 2016 | PR-inside.com

    ... Ilhavo, Portugal - SADIF Investment Analytics, announces a new summary due diligence report covering Corcept Therapeutics Incorporated [..] SADIF Analytics releases new summary due diligence [..] Ilhavo, Portugal - SADIF Investment Analytics, ...

    Comment?

  12. SADIF Analytics releases new summary due diligence report for Pfizer Inc.Read the original story w/Photo

    Jun 2, 2016 | PR-inside.com

    ... Ilhavo, Portugal - SADIF Investment Analytics, announces a new summary due diligence report covering Corcept Therapeutics Incorporated [..] SADIF Analytics releases new summary due diligence [..] Ilhavo, Portugal - SADIF Investment Analytics, ...

    Comment?

  13. SADIF Analytics releases new summary due diligence report for Corcept ...Read the original story w/Photo

    Jun 2, 2016 | PR-inside.com

    SADIF Investment Analytics, announces a new summary due diligence report covering Corcept Therapeutics Incorporated . The report uses SADIF's powerful StockMarks stock rating system and contains important analysis for any current or potential Corcept Therapeutics Incorporated investor.

    Comment?

  14. BlackRock Group LTD Increases Position in Corcept Therapeutics IncorporatedRead the original story w/Photo

    May 30, 2016 | Daily Political

    BlackRock Group LTD boosted its stake in shares of Corcept Therapeutics Incorporated by 60.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission . The firm owned 21,848 shares of the company's stock after buying an additional 8,265 shares during the period.

    Comment?

  15. Goldman Sachs Group Inc. Acquires 1,777 Shares of Corcept Therapeutics IncorporatedRead the original story w/Photo

    May 24, 2016 | Daily Political

    Goldman Sachs Group Inc. raised its position in shares of Corcept Therapeutics Incorporated by 3.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission . The fund owned 50,954 shares of the company's stock after buying an additional 1,777 shares during the period.

    Comment?

  16. Zacks: Corcept Therapeutics Incorporated (NASDAQ:CORT) Receives...Read the original story w/Photo

    May 21, 2016 | Daily Political

    Shares of Corcept Therapeutics Incorporated have been given a consensus broker rating score of 1.75 from the four analysts that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a sell rating and three have issued a strong buy rating on the company.

    Comment?

  17. Corcept Therapeutics Incorporated (NASDAQ:CORT) Receives Consensus...Read the original story w/Photo

    May 19, 2016 | AmericanBankingNews.com

    Corcept Therapeutics Incorporated has been assigned a consensus broker rating score of 1.75 from the four brokers that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a sell rating and three have given a strong buy rating to the company.

    Comment?

  18. Wednesday 5/11 Insider Buying Report: CORT, NEWMRead the original story

    May 11, 2016 | MarketNewsVideo

    ... a purchase, is that they expect to make money. Today we look at two noteworthy recent insider buys. At Corcept Therapeutics, a filing with the SEC revealed that on Tuesday, Director G. Leonard Baker Jr. bought 100,000 shares of CORT, for a cost of ...

    Comment?

  19. G Leonard Baker, Jr. Acquires 100,000 Shares of Corcept Therapeutics Incorporated (CORT) StockRead the original story w/Photo

    May 10, 2016 | AmericanBankingNews.com

    Corcept Therapeutics Incorporated Director G Leonard Baker, Jr. bought 100,000 shares of Corcept Therapeutics stock in a transaction that occurred on Tuesday, May 10th. The stock was purchased at an average cost of $4.88 per share, with a total value of $488,000.00.

    Comment?

  20. Corcept Therapeutics Incorporated (CORT) Stock Rating Reaffirmed by FBR & Co.Read the original story w/Photo

    May 6, 2016 | Daily Political

    ... equities research analysts at FBR & Co. in a report issued on Wednesday, Marketbeat reports. Shares of Corcept Therapeutics ( NASDAQ:CORT ) traded down 0.83% during midday trading on Wednesday, hitting $4.78. 146,342 shares of the stock traded ...

    Comment?